Daniel J. Wallace

41.5k total citations · 7 hit papers
292 papers, 16.3k citations indexed

About

Daniel J. Wallace is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel J. Wallace has authored 292 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Rheumatology, 115 papers in Immunology and 67 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel J. Wallace's work include Systemic Lupus Erythematosus Research (193 papers), Monoclonal and Polyclonal Antibodies Research (62 papers) and T-cell and B-cell Immunology (44 papers). Daniel J. Wallace is often cited by papers focused on Systemic Lupus Erythematosus Research (193 papers), Monoclonal and Polyclonal Antibodies Research (62 papers) and T-cell and B-cell Immunology (44 papers). Daniel J. Wallace collaborates with scholars based in United States, United Kingdom and Germany. Daniel J. Wallace's co-authors include Michael H. Weisman, Joan T. Merrill, Michelle Petri, Richard Furie, Ellen M. Ginzler, James R. Klinenberg, Mariana Linker‐Israeli, Kenneth Kalunian, David Isenberg and William Stohl and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Daniel J. Wallace

280 papers receiving 15.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

2011 1.1k citations Richard Furie, Michelle Petri et al. Arthritis & Rheumatism profile →
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

2009 972 citations Joan T. Merrill, C. Michael Neuwelt et al. Arthritis & Rheumatism profile →
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

2005 766 citations Ellen M. Ginzler, Jill P. Buyon et al. profile →
Dubois' Lupus Erythematosus

1988 560 citations Daniel J. Wallace profile →
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

2005 502 citations Daniel J. Wallace, Michael H. Weisman et al. Arthritis & Rheumatism profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

2018 356 citations Daniel J. Wallace, Richard Furie et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Michelle Petri, Ronald van Vollenhoven et al. profile →

Peers

Countries citing papers authored by Daniel J. Wallace

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Wallace more than expected).

Fields of papers citing papers by Daniel J. Wallace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Wallace. The network helps show where Daniel J. Wallace may publish in the future.

Co-authorship network of co-authors of Daniel J. Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Wallace. A scholar is included among the top collaborators of Daniel J. Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Wallace. Daniel J. Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Loss of Tripartite Motif–Containing Protein 21 and UVB ‐Induced Systemic Inflammation by Regulating DNA ‐Sensing Pathways 2025 ·Arthritis & Rheumatology ·Gantsetseg Tumurkhuu, (unknown), Richard E. Moore, Lihong Huo, (unknown), Richard I. Ainsworth, (unknown), (unknown), David R. Gibb, Jessica Carrière, Jeong Min Yu, Rachel Abuav, Lindsy Forbess, Daniel J. Wallace, Mariko Ishimori, Wonwoo Shon, Christian Stehlik, Caroline A. Jefferies	2
2	Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics 2025 ·Lara D. Veeken ·Jasvinder A. Singh, Larry R. Hearld, Seth A. Eisen, Winn Chatham, Sonali Narain, Narender Annapureddy, (unknown), (unknown), Vikas Majithia, Cathy Lee Ching, (unknown), (unknown), Daniel J. Wallace, Rosalind Ramsey‐Goldman, Alfred H.J. Kim, Maureen McMahon, S. Sam Lim, (unknown), Alexa Meara, Kenneth Kalunian, Mark Beasley, (unknown), (unknown), (unknown), (unknown), Jackson, (unknown), (unknown), (unknown), (unknown), (unknown)	0
3	Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity 2025 ·Lupus Science & Medicine ·Melissa E. Munroe, Kendra A. Young, Rufei Lu, Joel M. Guthridge, Diane L. Kamen, Gary S. Gilkeson, Michael H. Weisman, Mariko Ishimori, Daniel J. Wallace, David R. Karp, George C. Tsokos, Michael P. Keith, John B. Harley, Jill M. Norris, Judith A. James	1
4	Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial 2024 ·Lupus Science & Medicine ·Jane E. Salmon, Daniel J. Wallace, Violeta Rus, (unknown), (unknown), (unknown), Yunpeng Ding, Petter‐Arnt Hals, Line Johnsen, Peter E. Lipsky	3
5	Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology 2024 ·Arthritis & Rheumatology ·Ghaith Noaiseh, (unknown), Jennifer K. King, Arun S. Varadhachary, (unknown), Brent P. Goodman, Katherine M. Hammitt, Julie Frantsve‐Hawley, Robert J. Fox, Matthew Baker, Stamatina Danielides, Steven Mandel, (unknown), R. Hal Scofield, Daniel J. Wallace, Nancy Carteron, Steven E. Carsons	0
6	Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome 2024 ·Lara D. Veeken ·Daniela Ospina Cardona, Ignasi Rodríguez‐Pintó, (unknown), Núria Bonet, Anna Mensa‐Vilaró, (unknown), (unknown), (unknown), Jordi Yagüe, Wonwoo Shon, Daniel J. Wallace, Ferrán Casals, David B. Beck, Rachel Abuav, Juan I. Aróstegui	2
7	POS1130 DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME 2023 ·Annals of the Rheumatic Diseases ·Jesse J. Hubbard, Kim Campbell, Kathy L. Sivils, Robert W. Hoffman, Kim Hung Lo, Jocelyn H. Leu, Simon Bowman, Stephanie M. Liva, Qing Zuraw, Anne M. Stevens, Lei Ling, (unknown), Sindhu Ramchandren, Hui Sun, R. Hal Scofield, Raphaèle Séror, Daniel J. Wallace	1
8	Resampling Imbalanced Network Intrusion Datasets to Identify Rare Attacks 2023 ·Future Internet ·Sikha Bagui, (unknown), (unknown), Subhash Bagui, Sakthivel Subramaniam, Daniel J. Wallace	7
9	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus 2021 ·ACR Open Rheumatology ·Brian J. Skaggs, Jennifer Grossman, Lori Sahakian, (unknown), John FitzGerald, Christina Charles‐Schoeman, Alan Gorn, Mihaela Taylor, John M. Moriarty, Nagesh Ragavendra, Michael H. Weisman, Daniel J. Wallace, Bevra H. Hahn, Maureen McMahon	20
10	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus 2019 ·Arthritis & Rheumatology ·Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, Richard Furie, William Stohl, Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Michelle Petri, James Fettiplace, David A. Roth, Beulah Ji, Amy Heath	84
11	Raynaud’s Phenomenon From PD-1 Immune Checkpoint Inhibition 2019 ·JCO Oncology Practice ·(unknown), Adrian Jones, (unknown), Veronica Placencio-Hickok, Daniel J. Wallace, Jun Gong, Andrew Hendifar	2
12	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices 2015 ·The Journal of Rheumatology ·Joyce Hui‐Yuen, (unknown), Jennifer Taylor, Xiaoqing Li, Andrew H. Eichenfield, (unknown), (unknown), Lisa F. Imundo, Jill P. Buyon, Richard Furie, Diane L. Kamen, Susan Manzi, Michelle Petri, Rosalind Ramsey‐Goldman, Ronald van Vollenhoven, Daniel J. Wallace, Anca Askanase	75
13	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab 2013 ·Blood ·Edmund A. Rossi, David M. Goldenberg, Rosana Michel, Diane L. Rossi, Daniel J. Wallace, Chien‐Hsing Chang	88
14	Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study 2013 ·Arthritis & Rheumatism ·Michelle Petri, Daniel J. Wallace, Alberto Spindler, Vishala Chindalore, Kenneth Kalunian, Eduardo Mysler, C. Michael Neuwelt, Gabriel J. Robbie, Wendy I. White, Brandon W. Higgs, Yihong Yao, Liangwei Wang, D Ethgen, Warren Greth	200
15	Prescribing trends for targeted therapies in rheumatoid arthritis among rheumatologists in Southern California, 2008–2010 2011 ·Arthritis & Rheumatism ·(unknown), Daniel J. Wallace	1
16	Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs) 2008 ·Arthritis & Rheumatism ·Daniel J. Wallace, Frédéric Houssiau, Kathryn Hobbs, Vibeke Strand, Paul‐Peter Tak, William A. Wegener, (unknown), (unknown)	22
17	The Lupus Book 2005 ·Daniel J. Wallace	1
18	Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus 2004 ·Expert Opinion on Drug Safety ·(unknown), Daniel J. Wallace	26
19	Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. 1997 ·Journal of Clinical Investigation ·Betty P. Tsao, Rita M. Cantor, Kenneth Kalunian, (unknown), Humeira Badsha, Singh Rg, Daniel J. Wallace, Rodanthi C. Kitridou, (unknown), Nan Shen, Y.W. Song, David Isenberg, Chenglong Yu, Beatrice H. Hahn, Jerome I. Rotter	202
20	Systemic Lupus Erythematosus: Considerations for a Genetic Approach. 1994 ·Journal of Investigative Dermatology ·John B. Harley, Peter Sheldon, Barbara R. Neas, (unknown), Daniel J. Wallace, R. Hal Scofield, Timothy Shaver, Kathy L. Moser	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact